AstraZeneca sets ambition to deliver $80 billion Total Revenue by …
May 21, 2024 · AstraZeneca’s ambitions, forecasts and targets in this announcement (the “Financial Ambition Statements”) are derived from AstraZeneca’s most recent risk-adjusted …
Media Centre - AstraZeneca
Dec 8, 2024 · AstraZeneca Media centre. The Hub for our Articles, Press Releases and Webcasts & Presentations.
AstraZeneca - Research-Based BioPharmaceutical Company
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
9M and Q3 2024 results - astrazeneca.com
Nov 12, 2024 · Additionally, the quality and impact of our scientific research was well recognised this quarter with data for AstraZeneca medicines featuring in an unprecedented five …
AstraZeneca China President currently under investigation
Oct 30, 2024 · Leon Wang, Executive Vice President International and AstraZeneca China President, is cooperating with an ongoing investigation by Chinese authorities. Our China …
AstraZeneca completes equity investment agreement with Cellectis
May 6, 2024 · Post-closing of this second investment, AstraZeneca holds a total equity stake of c.44% in Cellectis. AstraZeneca expects to continue to treat its investment in Cellectis as an …
Imfinzi granted Priority Review and Breakthrough Therapy
Aug 15, 2024 · AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), based on the results from the positive ADRIATIC Phase III trial in patients with …
Datopotamab deruxtecan new BLA submitted for accelerated …
Nov 12, 2024 · AstraZeneca and Daiichi Sankyo’s new application is based on the TROPION-Lung05 Phase II trial and supported by data from additional trials including TROPION-Lung01 …
Imfinzi approved in the US as first and only immunotherapy …
Dec 5, 2024 · AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not …
9M and Q3 2023 results - AstraZeneca
Nov 9, 2023 · Pascal Soriot, Chief Executive Officer, AstraZeneca, commenting on the results said: “Our company continued its strong growth trajectory in the third quarter with Total …
- Some results have been removed